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ABSTRACT (word count 242) 
 
Background: Cardiovascular disease remains the major contributor to morbidity and mortality. In 
routine care for patients with an elevated cardiovascular risk or with symptomatic cardiovascular 
disease information is mostly collected in an unstructured manner, making the data of limited use for 
structural feedback, quality control, learning and scientific research.  
 
Objective: The Utrecht Cardiovascular Cohort (UCC) initiative aims to create an infrastructure for 
uniform registration of cardiovascular information in routine clinical practice for patients referred for 
cardiovascular care at the University Medical Center Utrecht. This infrastructure will promote 
optimal care according to guidelines, continuous quality control in a learning  health care system and 
creation of a research database.  
 
Methods: The UCC comprises three parts. UCC-1 comprises enrolment of all eligible cardiovascular 
patients in whom the same information will be collected, based on the Dutch cardiovascular 
management guideline. A sample of UCC-1 will be invited for UCC-2. UCC-2 involves an enrichment  
through extensive clinical measurements with emphasis on heart failure, cerebral ischemia, arterial 
aneurysms, diabetes mellitus and elevated blood pressure. UCC-3 comprises on-top studies, with in 
depth measurements in smaller groups of participants typically based on dedicated project grants. All 
participants are followed up for morbidity and mortality through linkage with national registries.  
 
Conclusion: In a multidisciplinary effort with physicians, patients and researchers the UCC sets a 
benchmark for a learning cardiovascular health care system. UCC offers an invaluable resource for 
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Introduction 
Patients with increased risk of cardiovascular disease (CVD), or those with symptoms potentially 
related to presence of cardiovascular abnormalities are commonly referred to various specialists, 
including cardiologists, endocrinologists, geriatricians, nephrologists, neurologists, internists, or 
vascular surgeons. Guidelines exist as to what should be recorded as a minimum in those 
patients.(1,2) Yet, compliance to these recommendations varies considerably across specialties(3) as  
each specialty collects a specific set of patient data, depending on signs and symptoms and the 
suspected condition. Furthermore, definitions and coding of data vary and location of information in 
the electronic health records shows marked variability. In specialist care, patients are followed only if 
the condition demands repeat visits. If it does not, patients return to the referring physician in 
another hospital or their general practitioner. Complete short and long term follow-up information is 
of major importance to determine quality and outcome of care but is often lacking.(4). It is well 
established that a steady flow of reliable data collected in routine clinical practice are the lifeblood of 
a continuous learning health care system. A learning healthcare system is one designed to generate 
and apply the best evidence for the collaborative healthcare choices of each patient and provider; to 
drive the process of discovery as a natural outgrowth of patient care; and to ensure innovation, 
quality, safety, and value in health care.(5). Data are needed to coordinate and monitor patient care, 
analyze and improve systems of care and its quality, conduct scientific research to develop new 
products and approaches, assess the effectiveness of medical interventions, and advance population 
health.(5)  
   In 2010 the University Medical Center Utrecht (UMC Utrecht) formulated a new strategy for 
academic patient care and research with a main focus on a selected number of major disease areas 
in which the UMC Utrecht has particular strengths and interests. This lead to the establishment of 
the Center for Circulatory Health in which all departments taking care for cardiovascular patients 
unite to integrate their patient care, research and educational activities. To enable continuous 
monitoring of clinical performance and quality of care, and to promote high quality research across 
all domains of CVD, the Utrecht Cardiovascular Cohort (UCC) was initiated. UCC provides an 
infrastructure for uniform registration of cardiovascular information embedded in routine care and 
for systematic follow-up of these patients. UCC builds on the experience of the Second 
Manifestations of ARTerial disease cohort at the UMC Utrecht(6,7), an initiative that started in 1996 
and enrolled over 12,000 patients.   
   The UCC infrastructure is meant to improve care and enable the collection of data to address 
diagnostic, etiologic, prognostic and therapeutic research questions. The UCC is governed and run by 
the Center for Circulatory Health at the UMC Utrecht. 
 




UCC is designed as a prospective cohort study and comprises three parts. UCC-1 comprises 
enrolment of all eligible CVD patients in whom information will be collected in routine clinical care. 
From UCC-1 participants, a large sample will be invited for UCC-2, which involves an enrichment of 
the information through more extensive measurements. Finally, UCC-3 involves specific 
measurements in selected samples of UCC participants, typically based on project grants. Broad 
informed consent is obtained in UCC-1 for storage of blood samples, follow-up procedures, and for 
contacting participants in the future. For the UCC-2 and UCC-3, study specific informed consents are 




All patients who come for a first-time visit to one of the departments of the Center for Circulatory 
Health at the UMC Utrecht for the evaluation of a symptomatic vascular disease or an asymptomatic 
vascular condition, are enrolled (departments listed in table 1). Minimum set of data, according to 
the Dutch Cardiovascular Risk Management Guidelines,(1) is collected in all patients at all 
departments. Annual number of eligible patients is 6,500 patients (UCC-1 population).  
   In UCC-2 measurements will be performed that are in part based on existing guidelines for clinical 
care (2,8-16), and in part driven by science. These measurements will be done in a sample of UCC-1 
participants who are at “very high CVD risk” as defined by the 2016 European Guidelines on 
cardiovascular disease prevention in clinical practice (2). The very high risk population comprises 
patients with documented CVD (including previous acute myocardial infarction, acute coronary 
syndrome, coronary revascularization and other arterial revascularization procedures, heart failure, 
stroke and TIA, aortic aneurysm and peripheral arterial disease); patients with documented CVD on 
imaging (including plaque on coronary imaging or carotid ultrasound); patients with diabetes mellitus 
and signs of end organ damage (proteinuria) or with a major risk factor such as smoking or marked 
hypercholesterolemia or marked hypertension; patients with severe renal impairment (eGFR <30 
mL/min/1.73 m2); or patients with a calculated HEART SCORE of 10% or above.(2) To expand the 
distribution of risk and risk factors into non-disease or non-referred range, addition of a population 
sample is needed to allow studying the complete cardiovascular spectrum and follow individuals that 
move into care. Therefore, we include an age- and sex stratified sample from the general population, 
i.e., 2000 participants from the Utrecht Health Project(17), an ongoing cohort in a new suburb of the 
city of Utrecht where in all new inhabitants that participate information is collected similar to that of 
UCC-1 participants. Over 10,000 individuals have been enrolled.  




A questionnaire is completed which includes demographic data, medical history, family history of 
premature CVD, physical activity, smoking, alcohol consumption, obstetric history and medication 
use (table 2). New patients referred for elective non-acute care receive the questionnaire at home in 
advance to be completed on-line through a secure patient portal or on paper. In case of the latter, 
data are entered into the electronic health record during the hospital visit assisted by a staff member 
if needed. A same approach is used for patients admitted with an acute vascular problem (figure 1). 
Relevant questionnaire information is directly accessible to the treating physician.  
   Measurements taken during the first visit in the hospital include body weight, height, systolic and 
diastolic blood pressure, serum lipids (total cholesterol, HDL cholesterol, triglycerides), glycated 
haemoglobin (Hb1Ac), renal function (serum creatinine with glomerular filtration rate (eGFR) 
estimated using the Chronic Kidney Disease-Epidemiology (CKD-EPI) formula), and haemoglobin. 
Spare blood samples (heparin, full blood) are taken and stored at -80 degrees Celsius.  
   Ethnic minority is considered if when at least one of the parents was born abroad.(18) 
Socioeconomic status (SES) is defined based on an area-level indicator by four-digit postal code, 
constructed by the Netherlands Institute for Social Research.(18) 
 
UCC-2 measurements 
The measurements reflect the main research priorities of the Center for Circulatory Health of the 
UMC Utrecht: heart failure, cerebral ischemia, arterial aneurysms, diabetes mellitus and elevated 
blood pressure.  
   A food frequency questionnaire will be used to measure dietary intake. Dognitive function, 
dyspnea, anxiety, depression, quality of life will be assessed. Questionnaires can be completed 
through an on-line a secure patient portal or on paper. Next to regular office blood pressure 
measurements, we include a 30 minute supine automated blood pressure measurement as a good 
approximation for 24 hour ambulatory measurements (19). A spot urine sample is taken to assess 
(micro)albuminuria, proteinuria and sodium and potassium creatinine ratio. As part of an in depth 
diagnostic work-up in patients with difficult to control elevated blood pressure, 24 hour urine sample 
is collected.(20).  
   A twelve lead resting electrocardiogram is made. An echocardiogram is performed for ventricular 
dimensions and cardiac function and to diagnose (subclinical) heart failure including heart failure 
with preserved left ventricular ejection fraction.(21-23) An ankle-brachial index  is measured.(24) 
Data on arterial calcifications and arterial dimensions (aneurysms) will come from a low dose 
thoracic and abdominal CT scan.(25-27) For young  information on atherosclerosis will be obtained 
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using ultrasound: Common carotid intima-media thickness, arterial wall density and presence and 
extent of carotid plaques using established techniques.(28,29) In a selected set of participants, 
cerebral magnetic resonance imaging is performed to assess intracranial atherosclerosis and 
aneurysms.  Information on intra-abdominal adiposity will be extracted from CT imaging.   
   A limited set of laboratory measurements will be done including  high-sensitivity C- reactive 
protein, thyroid stimulating hormone,  amino-termninal B-type natriuretic peptide (NTproBNP), 
lipoprotein  and high sensitivity troponin.(2,8-16) Also an additional venous blood sample will be 
stored in -80 Celsius in the UMC Utrecht Biobank for future  research. 
 
UCC- follow-up 
UCC participants are followed for the occurrence of non-fatal and fatal events. To track patients the 
Dutch population register is used which contains information on all individuals living in the 
Netherlands, including date of birth, sex, current address, postal code, nationality, native country 
(both of registered person and his/her parents), date of death or date of emigration.(30) Routinely 
performed clinical follow-up measurements  and treatment in the UMC Utrecht will be obtained 
from the electronic health records. In addition, information on hospital admissions will be obtained 
through linkage with the national Dutch Hospital Data (DHD) registry which provides hospital 
discharge data including  primary and secondary diagnoses, dates of hospital admission and 
discharge, and has a 90% coverage. Data are coded according to the WHO International Classification 
of Diseases version 10 (ICD-10).(31). Primary and secondary cause of death will be obtained through 
linkage with the National Cause of Death Registry.(30) Prescribed drugs during follow-up will be 
derived from the Foundation on Pharmaceutical Statistics that covers over 95 % of the community 
pharmacies in The Netherlands.(32) Data on dialysis and kidney transplantation will be obtained from 
the RENINE registers.(33) Information on cancer incidence will be obtained through the Netherlands 
Cancer Registry.(34) Furthermore, information will be obtained through contacts with the Utrecht 
General Practitioners Network.(35) Finally, UCC-2 participants regularly receive questionnaires on 
clinical outcome, including new onset diabetes and hypertension, and quality of life and lifestyle 
changes.(6,7)  
   To facilitate linkage of databases , the Mondriaan system, sponsored by the Dutch Ministry of 
Health, is important. Mondriaan uses privacy enhancing technologies such as the use of datashields 
and Trusted Third Parties for linkage of data sources and allows access to various healthcare and 
research data.(36) Furthermore, the system allows selection and approach of subjects for additional 
clinical research like clinical trials and pharmacogenetic studies and includes a data catalogue for 
simple queries over the integrated databases.  
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Privacy issues 
A written informed consent is needed for individual personalized deterministic linkage with regional 
and national registries in agreement with the privacy legislation in the Netherlands using established 
procedures.(36) In case of informed consent there are no privacy issues and linkage occurs using a 
deterministic approach. In case of no informed consent, a trusted third party (TTP) interference may 
be needed to apply probability based linkage algorithms for regional and national registries to obtain 
follow-up information on events (hospitalisation, various disease incidence (e.g. cancer), use of 
general practitioners care, mortality, and prescribed medicine ).  
 
Feedback to treating physicians 
Abnormal UCC-1 findings are reported back to the treating physician as part of routine care. UCC-2 
results for each patient are discussed at a weekly multidisciplinary team meeting (internist, vascular 
surgeon, cardiologist, neurologist, radiologist, nurse practitioner) to arrive at an individualized 
treatment advice regarding vascular risk management. Subsequently, treatment is started and the 
patient is scheduled for two visits at the UMC Utrecht, after which UCC-2 results joined with 
treatment advice and its findings are reported in writing to the treating specialist and the general 
practitioner. Recommendations comply to Dutch guidelines which are broadly in agreement with the 
recent ESC prevention guidelines (1,2). 
 
Data management and access 
The data management group of the Center for Circulatory Health ensures privacy, security and 
traceability and is ISO 9000 certified. Investigators from the participating departments of Center for 
Circulatory Health have free access to the UCC database. Researchers can request existing data and 
samples for analysis of new markers. Tailor made datasets will be distributed to the investigator 
upon approval of request by the UCC Steering Committee. Approval mainly involves checking 
feasibility, potential overlap with previous requests, material availability, and need for involvement 
of specific disciplines. After data distribution, automated checks on progress will be made at regular 
intervals. For investigators outside these departments or from outside the UMC Utrecht, a similar 
procedure is available. When new variables are measured in stored samples these must be added the 
UCC database. A copy of the distributed dataset remains at the UMC Utrecht for long term storage. 
Details on available data, the application form and procedure can be found on our website. For 
researchers outside participating departments we charge a data access fee per dataset to cover our 
costs for inclusion, maintenance, quality control and management. 
 
Current status   
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As of December 12, 2016, over 1000 patients have been invited for UCC-1. Of those, overall 53% gave 
a written informed consent, but varied across departments (e.g., 34% at the geriatrics outpatient 
clinic (mean age 80 years), 65% at the diabetes outpatient clinic, or 77% at the neurology ward 
(patients admitted for a stroke). Response rates are weekly given to the research group to be 
discussed with the health care workers responsible for the enrolment. UCC-2 shall start in 2017. 
 
Discussion 
The UCC is set up to provide an infrastructure and a set of governing principles for uniform 
registration of essential data for patient care and research in all patients referred for cardiovascular 
evaluation to  the Center for Circulatory Health at the UMC Utrecht. UCC promotes guideline based 
optimal care, creates a continuous database for multidisciplinary cardiovascular research and 
provides a quality control system with structured analysis and reporting of clinical information and 
advice to specialist working in the hospital and referring physicians. Based on the registered 
information in usual care physicians get predefined feedback on their performance (feedback 
prioritized by the physicians), have regular discussions on the feedback findings (with management, 
colleagues, researchers), may modify behaviour and potentially treatment approaches. This circle is 
developed bottom-up in close collaboration with the nurses and physicians, the data management 
and IT people to see what the options for improvement are within the electronic health record 
software. The  learning cardiovascular health system will be further be optimized in detail during the 
next years. UCC sets a benchmark for a learning cardiovascular health care system. Our previous 
experience has shown that a structured program indeed improves health.(37)  
   In addition to an invaluable resource for high quality care and prevention, UCC offers first class 
research opportunities. The necessity of studies as the UCC were strongly advocated in a recently 
published series on the future of cardiovascular medicine.(38,39) The potential for research is 
multiple, including generation of clinical evidence for health care, like clinical trials and effectiveness. 
The concept of embedding clinical trials within pre-enrolled cohorts has gained enthusiasm.(40) The 
availability of a procedure of routinely collecting patient data greatly speeds up the assessment 
process for interventions. Structured databases can be queried for specific in- and exclusion criteria 
to identify and screen patients for clinical trials, and can be used to ascertain potential end points  in 
trials. Since data are already in place, conducting clinical research does not require building new 
infrastructure nor collecting new data. The UCC approach is combined in the electronic health record 
with unstructured clinical information (clinical notes, physical notes or discharge summaries) and test 
results (radiology reports). That structure also allows for application and evaluation of various of text 
mining strategies to for example identify individual risks for personalized treatment approaches, and, 
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when combined with genetic information, be of use for pharmacogenomics research and patient 
care.(41) 
   The development, validation, and use of risk prediction models to inform health care, including risk 
interpretation by individuals, has been singled out as holding great promise.(38,39) The evaluation of 
risk prediction models that identify which patients benefit most from interventions, from trial results 
to individualized prediction (42), can be swiftly evaluated and validated. The inclusion of the full 
spectrum of subjects from healthy to severely diseased allows for life course studies into the 
development of the various phases of vascular disease,  its main drivers and its consequence in terms 
of morbidity and mortality.(43) 
   The UCC has obvious challenges and limitations. We aimed to optimally balance the burden and 
cost associated with its collection (impact on usability) and its value (usefulness of data) through 
focus, and so had to restrict on availability of measurements and patient groups. Other patient 
categories with an increased cardiovascular risk may benefit from an approach like UCC, for example 
those with systemic inflammatory conditions are presently not yet included in UCC.  Also, the UCC is 
limited to patients referred to a tertiary academic center, which is of relevance for generalizability of 
findings in clinical care and research. However, the UCC approach is certainly transferable to other 
hospitals , given sufficient effort, dedication, time, and support from all layers of a hospital combined 
with certain budgets.  
   In summary, in collaborative effort by physicians, researchers and patients,  the UCC sets a 
benchmark for a learning cardiovascular health care system and offers an invaluable resource for 
high quality care and prevention as well as cutting edge research for investigators from the UMC 
Utrecht and other institutions.   
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Table 1. Participating divisions and departments in the UMC Utrecht 
_________________________________________________________________________________ 
 
Division Brain Center Rudolf Magnus 
 Neurology and Neurosurgery 
Division Heart and Lungs  
 Cardiology 
 Laboratory for Circulatory Health  
 Cardio-Thoracic Surgery 
Division Internal Medicine 
 Endocrinology 
 Geriatric Medicine 
 Infectious Disease 
 Nephrology and Hypertension 
 Vascular Medicine  
Division Imaging and Nuclear Medicine 
 Radiology 
Division Julius Center for Health Sciences and Primary Care 
 Clinical Epidemiology 
 Primary Care 
Division Laboratories and Pharmacy 
 Clinical Chemistry and Haematology 
Division Surgical Disciplines 
 Vascular Surgery 
Division Vital Functions 
 Anesthesiology and Intensive Care 
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Table 2. Information collected in UCC-1 
Demography:    date of enrollment /date of birth/sex/postal code. 
General aspects:   treating physician/indication for referral 
Medical history:   acute myocardial infarction/CABG/ PTCA/heart failure 
    TIA/stroke/intermittent claudication/Aneurysm  
    Chronic kidney disease/hypertension/hyperlipidemia 
    Family history/Obstetric history  
Life style:    Education/smoking/alcohol consumption/physical activity 
Physiological measurements:  Height/weight/blood pressure/heart rate 
Laboratory measurements: Total cholesterol/LDL/HDL/Triglycerides/Creatinine/(eGFR)/ 
     HbA1c/Hemoglobin 
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